Vigil Neuroscience Inc. (VIGL)
1.78
0.10 (5.95%)
At close: Apr 02, 2025, 3:59 PM
1.82
2.25%
After-hours: Apr 02, 2025, 07:57 PM EDT
5.95% (1D)
| Bid | 1.58 |
| Market Cap | 83.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.07 |
| PE Ratio (ttm) | -0.86 |
| Forward PE | -1.06 |
| Analyst | Buy |
| Ask | 1.85 |
| Volume | 122,274 |
| Avg. Volume (20D) | 1,043,436 |
| Open | 1.67 |
| Previous Close | 1.68 |
| Day's Range | 1.66 - 1.81 |
| 52-Week Range | 1.49 - 6.06 |
| Beta | 1.84 |
About VIGL
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy wi...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 7, 2022
Employees 69
Stock Exchange NASDAQ
Ticker Symbol VIGL
Website https://www.vigilneuro.com
Analyst Forecast
According to 5 analyst ratings, the average rating for VIGL stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 686.52% from the latest price.
Stock Forecasts2 days ago
-6.81%
Vigil Neuroscience shares are trading lower. The c...
Unlock content with
Pro Subscription
2 weeks ago
-10.21%
Vigil Neuroscience shares are trading lower after the company a Q4 GAAP EPS miss.
